Kluwer Patent Blog

Patent case: Actavis Group PTC EHF v ICOS Corporation, United Kingdom

Sara Moran · Saturday, December 15th, 2018

The Court of Appeal overturned the Patent Court's first instance decision concerning the validity of one of ICOS's patents (licensed to Eli Lilly) covering a 1 to 5mg dosage form of tadalafil (Cialis®) for oral administration up to a maximum of 5mg per day for the treatment of sexual dysfunction. The Court held that the Judge had erred in concluding that the patent was not obvious, and made interesting comments on the requirement that the person skilled in the art would have a reasonable expectation of success in trying the invention.

Case date: 01 November 2017 Case number: [2017] EWCA Civ 1671 Court: Court of Appeal of England and Wales, Civil Division

A full summary of this case has been published on Kluwer IP Law.

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.


1

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law. The master resource for Intellectual Property rights and registration.





The Wolters Kluwer Future Ready Lawyer Leading change

This entry was posted on Saturday, December 15th, 2018 at 4:55 am and is filed under Case Law, Pharmaceutical patent, United Kingdom

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.